Press release archive 2001

Friday, 28 December 2001
AstraZeneca submits clinical data for IRESSA (ZD1839) – a new class of anti-cancer treatment - in the USA AstraZeneca today announced that it has submitted a clinical data package to the U.S. Food and Drug Administration (FDA) in support of IRESSA (ZD1839) as monotherapy for the treatment of advanced non-small cell lung cancer (NSCLC) in patients who have failed on previous chemotherapy regimens. IRESSA has been granted fast track review by the US authorities for this indication.
Friday, 21 December 2001
ASTRAZENECA SUBMITS SUPPLEMENTAL NEW DRUG APPLICATION TO FDA FOR CASODEX 150 MG FOR THE TREATMENT OF EARLY STAGE PROSTATE CANCER AstraZeneca today announced that a supplemental New Drug Application (sNDA) has been filed with the U.S. Food and Drug Administration (FDA) for the company’s oral, once-daily hormonal medication Casodex (bicalutamide 150mg) for the treatment of early stage non-metastatic prostate cancer.
Thursday, 20 December 2001
AstraZeneca and Lilly Collaborate on Clinical Trial Programmes To Study IRESSA™ (ZD1839) In Combination With Gemzar® (Gemcitabine) For the Treatment of Various Cancers AstraZeneca and Eli Lilly Company today announced their clinical collaboration to evaluate the benefits of IRESSA™ (ZD1839) in combination with Gemzar® (gemcitabine) for the treatment of various cancers. The clinical collaboration, which will be jointly funded by both companies, will initially assess the combination of the two treatments as part of a Phase II clinical trial programme involving patients with advanced stage non-small cell lung cancer (NSCLC) and bladder cancer. The companies also plan to
Tuesday, 11 December 2001
NEW DATA ON ARIMIDEX® HERALD ENTRY INTO EARLY BREAST CANCER AstraZeneca today announced that new data presented at the San Antonio Breast Cancer Meeting demonstrate for the first time that leading aromatase inhibitor Arimidex ® is significantly more effective and has important tolerability benefits compared with the current gold standard, tamoxifen, as an adjuvant treatment in postmenopausal women with early breast cancer.
Monday, 26 November 2001
ASTRAZENECA RECEIVES SIX MONTHS’ MARKET EXCLUSIVITY FOR ZESTRIL® (LISINOPRIL) AstraZeneca announced today that the U.S. Food and Drug Administration (FDA) granted six months’ market exclusivity for the ACE inhibitor ZESTRIL® (lisinopril) after the company complied with the FDA’s written request for information on the use of the medication in children.
Thursday, 1 November 2001
FIRST PHASE II STUDY RESULTS SHOW ANTI-TUMOUR ACTIVITY WITH IRESSA™ IN ADVANCED NON-SMALL CELL LUNG CANCER Preliminary data from the first pivotal phase II trial, presented today at the 12th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Miami, USA , demonstrate that when used as a second or third-line treatment, IRESSA™ leads to overall disease control in more than 50 per cent of unselected [1] patients with advanced non-small cell lung cancer (NSCLC) who have failed previous platinum-based therapy.
Wednesday, 31 October 2001
ASTRAZENECA WINS GENERIC OMEPRAZOLE CASE IN NORWAY AstraZeneca today announced that the Oslo Byrett (Oslo City Court) in Norway found that a generic omeprazole product marketed by Scandinavian Pharmaceuticals-Generics AB (Scand Pharm) infringes AstraZeneca’s formulation patent for omeprazole, the substance used in Losec. At the same time, the Court declared AstraZeneca’s omeprazole formulation patent valid.
Tuesday, 23 October 2001
PRILOSEC US LITIGATION AstraZeneca today announced that it had received confirmation that its pending litigation to defend its patents associated with Prilosec in the US will go to trial in a case to be heard by Judge Jones commencing in New York on December 5th 2001.
Friday, 19 October 2001
ZD1839 IRESSA DATA AstraZeneca is encouraged by the positive results from IDEAL 1 ( I RESSA D ose E valuation in A dvanced L ung cancer), the first pivotal study of ZD1839 (IRESSA) in non-small-cell-lung-cancer (NSCLC) and looks forward to the presentation of these phase II data at the 12th AACR-NCI-EORTC International Conference on "Molecular Targets and Cancer Therapeutics" in Miami, USA. Whilst the abstract of the data is available on www.aacr.org , the full results from IDEAL 1 will not be presented until Thursday,
Tuesday, 9 October 2001
NEXIUM® OUTPERFORMS LANSOPRAZOLE IN FIRST HEAD-TO-HEAD CLINICAL TRIALS Stanhope Gate, London, UK - The long-awaited results of head-to-head clinical trials between AstraZeneca’s newest proton pump inhibitor (PPI) therapy, Nexium® (esomeprazole), and its principal competitor, lansoprazole, were released today at the United European Gastroenterology Week (UEGW) in Amsterdam.